SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'CAU'
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
Interface | HETATM | RMSD | Dali Z-score |
Seq. Identity (%) |
View | Dock | |
---|---|---|---|---|---|---|---|---|---|---|---|
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_A_Y00A601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109ASP A 113VAL A 114PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.64A | 2y00A-4gbrA:39.3 | 2y00A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_A_Y00A601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109ASP A 113VAL A 114SER A 203PHE A 261PHE A 262ASN A 284 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.3A) | 1.40A | 2y00A-4gbrA:39.3 | 2y00A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_A_Y00A601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109ASP A 113VAL A 114SER A 203PHE A 261PHE A 262ASN A 284TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.74A | 2y00A-4gbrA:39.3 | 2y00A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_A_Y00A601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109ASP A 113VAL A 114SER A 203SER A 207PHE A 261PHE A 262TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.76A | 2y00A-4gbrA:39.3 | 2y00A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_A_Y00A601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109ASP A 113VAL A 114SER A 207PHE A 261PHE A 262ASN A 265TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-4.6A) | 0.66A | 2y00A-4gbrA:39.3 | 2y00A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_A_Y00A601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.49A | 2y00A-4gbrA:39.3 | 2y00A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_B_Y00B601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.48A | 2y00B-4gbrA:39.0 | 2y00B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_B_Y00B601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203PHE A 261PHE A 262 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A) | 1.32A | 2y00B-4gbrA:39.0 | 2y00B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_B_Y00B601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203SER A 207PHE A 261PHE A 262TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.70A | 2y00B-4gbrA:39.0 | 2y00B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_B_Y00B601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 207PHE A 261PHE A 262ASN A 265TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-4.6A) | 0.63A | 2y00B-4gbrA:39.0 | 2y00B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y00_B_Y00B601_2 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 3 / 3 | VAL A 117ASN A 284TRP A 285 | CAU A 500 (-4.2A)CAU A 500 (-3.3A)None | 0.65A | 2y00B-4gbrA:39.0 | 2y00B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y01_A_Y00A601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109ASP A 113PHE A 193PHE A 261PHE A 262ASN A 265ASN A 284TRP A 285TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-4.5A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)NoneCAU A 500 (-4.6A) | 0.72A | 2y01A-4gbrA:38.8 | 2y01A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y01_A_Y00A601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109ASP A 113PHE A 193SER A 203PHE A 261PHE A 262ASN A 284TRP A 285TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-4.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.3A)NoneCAU A 500 (-4.6A) | 0.84A | 2y01A-4gbrA:38.8 | 2y01A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y01_A_Y00A601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | TRP A 109ASP A 113SER A 207PHE A 262TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.19A | 2y01A-4gbrA:38.8 | 2y01A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y01_B_Y00B601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.48A | 2y01B-4gbrA:38.7 | 2y01B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y01_B_Y00B601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203PHE A 261PHE A 262 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A) | 1.28A | 2y01B-4gbrA:38.7 | 2y01B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y01_B_Y00B601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203SER A 207PHE A 261PHE A 262TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.69A | 2y01B-4gbrA:38.7 | 2y01B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y01_B_Y00B601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 207PHE A 261PHE A 262ASN A 265TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-4.6A) | 0.64A | 2y01B-4gbrA:38.7 | 2y01B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | TRP A 109ASP A 113VAL A 114SER A 203PHE A 261 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A) | 1.39A | 2y03A-4gbrA:39.4 | 2y03A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.48A | 2y03A-4gbrA:39.4 | 2y03A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 10 / 12 | TRP A 109ASP A 113VAL A 114VAL A 117PHE A 193PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.5A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.57A | 2y03A-4gbrA:39.4 | 2y03A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109ASP A 113VAL A 114VAL A 117PHE A 193SER A 203PHE A 261PHE A 262TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.65A | 2y03A-4gbrA:39.4 | 2y03A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | TRP A 109VAL A 114PHE A 193SER A 203SER A 207 | NoneCAU A 500 (-3.5A)CAU A 500 (-4.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A) | 0.97A | 2y03A-4gbrA:39.4 | 2y03A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | TRP A 109VAL A 114PHE A 193SER A 207ASN A 265 | NoneCAU A 500 (-3.5A)CAU A 500 (-4.5A)CAU A 500 (-4.1A)CAU A 500 (-3.4A) | 0.90A | 2y03A-4gbrA:39.4 | 2y03A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | VAL A 117PHE A 261ASN A 265ASN A 284TYR A 288 | CAU A 500 (-4.2A)CAU A 500 (-4.2A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 1.24A | 2y03A-4gbrA:39.4 | 2y03A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.48A | 2y03B-4gbrA:39.0 | 2y03B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203PHE A 261 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A) | 1.37A | 2y03B-4gbrA:39.0 | 2y03B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 10 / 12 | TRP A 109THR A 110ASP A 113VAL A 114VAL A 117PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.56A | 2y03B-4gbrA:39.0 | 2y03B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109THR A 110ASP A 113VAL A 114VAL A 117SER A 203PHE A 261PHE A 262TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.59A | 2y03B-4gbrA:39.0 | 2y03B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | TRP A 109THR A 110VAL A 114SER A 203SER A 207 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A) | 0.93A | 2y03B-4gbrA:39.0 | 2y03B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | TRP A 109THR A 110VAL A 114SER A 207ASN A 265 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-3.4A) | 0.90A | 2y03B-4gbrA:39.0 | 2y03B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | VAL A 117PHE A 261ASN A 265ASN A 284TYR A 288 | CAU A 500 (-4.2A)CAU A 500 (-4.2A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 1.28A | 2y03B-4gbrA:39.0 | 2y03B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y04_A_68HA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 11 / 11 | TRP A 109ASP A 113VAL A 114PHE A 193SER A 203SER A 207PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.64A | 2y04A-4gbrA:38.9 | 2y04A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y04_A_68HA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 11 | TRP A 109ASP A 113VAL A 114SER A 203PHE A 261PHE A 262ASN A 284 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.3A) | 1.28A | 2y04A-4gbrA:38.9 | 2y04A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y04_A_68HA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 11 | TRP A 109ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.36A | 2y04A-4gbrA:38.9 | 2y04A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y04_A_68HA601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 11 | VAL A 117PHE A 261ASN A 265ASN A 284TYR A 288 | CAU A 500 (-4.2A)CAU A 500 (-4.2A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 1.29A | 2y04A-4gbrA:38.9 | 2y04A-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y04_B_68HB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.45A | 2y04B-4gbrA:39.0 | 2y04B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y04_B_68HB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | THR A 110ASP A 113VAL A 114PHE A 193PHE A 262 | CAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.5A)CAU A 500 (-4.6A) | 1.34A | 2y04B-4gbrA:39.0 | 2y04B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y04_B_68HB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203PHE A 261PHE A 262ASN A 284 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.3A) | 1.26A | 2y04B-4gbrA:39.0 | 2y04B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 2Y04_B_68HB601_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 12 / 12 | TRP A 109THR A 110ASP A 113VAL A 114VAL A 117PHE A 193SER A 203SER A 207PHE A 261PHE A 262ASN A 284TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.52A | 2y04B-4gbrA:39.0 | 2y04B-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 3D4S_A_TIMA401_1 (BETA-2 ADRENERGICRECEPTOR/T4-LYSOZYMECHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 207PHE A 262ASN A 284TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 1.17A | 3d4sA-4gbrA:41.2 | 3d4sA-4gbrA:57.68 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 3D4S_A_TIMA401_1 (BETA-2 ADRENERGICRECEPTOR/T4-LYSOZYMECHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 12 / 12 | TRP A 109THR A 110ASP A 113VAL A 114VAL A 117SER A 203TRP A 258PHE A 262ASN A 265TYR A 280ASN A 284TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-3.3A)NoneCAU A 500 (-4.6A)CAU A 500 (-3.4A)NoneCAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.51A | 3d4sA-4gbrA:41.2 | 3d4sA-4gbrA:57.68 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 3D4S_A_TIMA401_2 (BETA-2 ADRENERGICRECEPTOR/T4-LYSOZYMECHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 3 / 3 | THR A 118SER A 207PHE A 261 | CAU A 500 ( 4.7A)CAU A 500 (-4.1A)CAU A 500 (-4.2A) | 0.15A | 3d4sA-4gbrA:41.2 | 3d4sA-4gbrA:57.68 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 3NYA_A_JTZA1203_1 (BETA-2 ADRENERGICRECEPTOR, LYSOZYME) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203PHE A 261PHE A 262ASN A 284TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 1.15A | 3nyaA-4gbrA:40.8 | 3nyaA-4gbrA:57.68 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 3NYA_A_JTZA1203_1 (BETA-2 ADRENERGICRECEPTOR, LYSOZYME) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 12 / 12 | TRP A 109THR A 110ASP A 113VAL A 114VAL A 117SER A 203SER A 207PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-3.3A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.47A | 3nyaA-4gbrA:40.8 | 3nyaA-4gbrA:57.68 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3QFX_A_CP6A602_1 (BIFUNCTIONALDIHYDROFOLATEREDUCTASE-THYMIDYLATE SYNTHASE) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | VAL A 117ALA A 78ASP A 79PHE A 254ILE A 121 | CAU A 500 (-4.2A)NoneNoneNoneNone | 1.18A | 3qfxA-4gbrA:undetectable | 3qfxA-4gbrA:21.29 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3RZE_A_D7VA1201_1 (HISTAMINE H1RECEPTOR, LYSOZYMECHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | ASP A 113THR A 118ILE A 121TRP A 258PHE A 262TYR A 288 | CAU A 500 (-3.0A)CAU A 500 ( 4.7A)NoneNoneCAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.73A | 3rzeA-4gbrA:31.0 | 3rzeA-4gbrA:25.37 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 4AMJ_A_CVDA1359_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 12 / 12 | TRP A 109ASP A 113VAL A 114VAL A 117SER A 203SER A 207TRP A 258PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-3.3A)CAU A 500 (-4.1A)NoneCAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.49A | 4amjA-4gbrA:39.5 | 4amjA-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 4AMJ_B_CVDB1360_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 11 / 12 | TRP A 109ASP A 113VAL A 117SER A 203SER A 207TRP A 258PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-4.2A)CAU A 500 (-3.3A)CAU A 500 (-4.1A)NoneCAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.51A | 4amjB-4gbrA:39.4 | 4amjB-4gbrA:58.02 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 4AMJ_B_CVDB1360_2 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 4 / 4 | VAL A 114ASP A 192TYR A 199TRP A 285 | CAU A 500 (-3.5A)NoneNoneNone | 0.52A | 4amjB-4gbrA:39.4 | 4amjB-4gbrA:58.02 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4IAR_A_ERMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 4 / 7 | TRP A 109THR A 118SER A 203PHE A 262 | NoneCAU A 500 ( 4.7A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.76A | 4iarA-4gbrA:29.5 | 4iarA-4gbrA:29.83 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4IB4_A_ERMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 2B AND E.COLI SOLUBLECYTOCHROME B562) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | VAL A 114TRP A 258PHE A 261PHE A 262VAL A 269 | CAU A 500 (-3.5A)NoneCAU A 500 (-4.2A)CAU A 500 (-4.6A)None | 0.65A | 4ib4A-4gbrA:27.3 | 4ib4A-4gbrA:29.05 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 4LDO_A_ALEA1402_1 (LYSOZYME, BETA-2ADRENERGIC RECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 10 | ASP A 113VAL A 114PHE A 193SER A 203SER A 207PHE A 261 | CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A)CAU A 500 (-4.2A) | 1.05A | 4ldoA-4gbrA:33.2 | 4ldoA-4gbrA:99.66 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 4LDO_A_ALEA1402_1 (LYSOZYME, BETA-2ADRENERGIC RECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 10 | ASP A 113VAL A 114PHE A 193SER A 207PHE A 261ASN A 265 | CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.5A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-3.4A) | 1.09A | 4ldoA-4gbrA:33.2 | 4ldoA-4gbrA:99.66 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 4LDO_A_ALEA1402_1 (LYSOZYME, BETA-2ADRENERGIC RECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 10 | ASP A 113VAL A 114VAL A 117PHE A 193PHE A 261ASN A 265TYR A 288 | CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.5A)CAU A 500 (-4.2A)CAU A 500 (-3.4A)CAU A 500 (-4.6A) | 0.82A | 4ldoA-4gbrA:33.2 | 4ldoA-4gbrA:99.66 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 4LDO_A_ALEA1402_1 (LYSOZYME, BETA-2ADRENERGIC RECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 10 | ASP A 113VAL A 114VAL A 117PHE A 193SER A 203PHE A 261TYR A 288 | CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A) | 0.86A | 4ldoA-4gbrA:33.2 | 4ldoA-4gbrA:99.66 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 4LDO_A_ALEA1402_1 (LYSOZYME, BETA-2ADRENERGIC RECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 10 | ASP A 113VAL A 114VAL A 117PHE A 261ASN A 265ASN A 284TYR A 288 | CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.2A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.80A | 4ldoA-4gbrA:33.2 | 4ldoA-4gbrA:99.66 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 5FSA_B_X2NB590_2 (CYP51 VARIANT1) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 3 / 3 | PRO A 211LEU A 259SER A 207 | NoneNoneCAU A 500 (-4.1A) | 0.82A | 5fsaB-4gbrA:0.0 | 5fsaB-4gbrA:20.98 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 6A93_A_8NUA3001_0 (5-HYDROXYTRYPTAMINERECEPTOR 2A,SOLUBLECYTOCHROME B562) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109THR A 118ILE A 121PHE A 254TRP A 258PHE A 261PHE A 262TYR A 288 | NoneCAU A 500 ( 4.7A)NoneNoneNoneCAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.67A | 6a93A-4gbrA:30.0 | 6a93A-4gbrA:29.19 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 6A93_B_8NUB3001_0 (5-HYDROXYTRYPTAMINERECEPTOR 2A,SOLUBLECYTOCHROME B562) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109VAL A 114THR A 118TRP A 258PHE A 261PHE A 262 | NoneCAU A 500 (-3.5A)CAU A 500 ( 4.7A)NoneCAU A 500 (-4.2A)CAU A 500 (-4.6A) | 0.51A | 6a93B-4gbrA:31.1 | 6a93B-4gbrA:29.19 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 6A93_B_8NUB3001_1 (5-HYDROXYTRYPTAMINERECEPTOR 2A,SOLUBLECYTOCHROME B562) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 4 / 5 | ASP A 113ILE A 121PHE A 254TYR A 288 | CAU A 500 (-3.0A)NoneNoneCAU A 500 (-4.6A) | 0.59A | 6a93B-4gbrA:31.1 | 6a93B-4gbrA:29.19 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 6A94_A_ZOTA3001_0 (5-HYDROXYTRYPTAMINERECEPTOR 2A,SOLUBLECYTOCHROME B562) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109SER A 207PHE A 254TRP A 258PHE A 261PHE A 262ASN A 265 | NoneCAU A 500 (-4.1A)NoneNoneCAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A) | 0.97A | 6a94A-4gbrA:32.0 | 6a94A-4gbrA:29.19 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 6A94_B_ZOTB3001_0 (5-HYDROXYTRYPTAMINERECEPTOR 2A,SOLUBLECYTOCHROME B562) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | VAL A 114THR A 118SER A 207PHE A 254TRP A 258PHE A 261PHE A 262 | CAU A 500 (-3.5A)CAU A 500 ( 4.7A)CAU A 500 (-4.1A)NoneNoneCAU A 500 (-4.2A)CAU A 500 (-4.6A) | 0.63A | 6a94B-4gbrA:31.4 | 6a94B-4gbrA:29.19 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 6CM4_A_8NUA2001_0 (D(2) DOPAMINERECEPTOR, ENDOLYSINCHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | PHE A 254TRP A 258PHE A 262TYR A 280TYR A 288 | NoneNoneCAU A 500 (-4.6A)NoneCAU A 500 (-4.6A) | 0.64A | 6cm4A-4gbrA:30.5 | 6cm4A-4gbrA:25.59 | ||
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 6CM4_A_8NUA2001_0 (D(2) DOPAMINERECEPTOR, ENDOLYSINCHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | VAL A 114THR A 118PHE A 254TRP A 258PHE A 262TYR A 288 | CAU A 500 (-3.5A)CAU A 500 ( 4.7A)NoneNoneCAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.74A | 6cm4A-4gbrA:30.5 | 6cm4A-4gbrA:25.59 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6DRX_A_H8GA1201_0 (5HT2B RECEPTOR, BRILCHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109VAL A 114THR A 118TRP A 258PHE A 261ASN A 265TYR A 288 | NoneCAU A 500 (-3.5A)CAU A 500 ( 4.7A)NoneCAU A 500 (-4.2A)CAU A 500 (-3.4A)CAU A 500 (-4.6A) | 0.93A | 6drxA-4gbrA:28.8 | 6drxA-4gbrA:30.19 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6DRY_A_H8DA2001_0 (5HT2B RECEPTOR, BRILCHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 11 | ASP A 113VAL A 114THR A 118PHE A 261TYR A 288 | CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 ( 4.7A)CAU A 500 (-4.2A)CAU A 500 (-4.6A) | 0.84A | 6dryA-4gbrA:26.6 | 6dryA-4gbrA:30.12 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6DRZ_A_H8JA1206_0 (5HT2B RECEPTOR, BRILCHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | VAL A 114THR A 118PHE A 261PHE A 262ASN A 265TYR A 288 | CAU A 500 (-3.5A)CAU A 500 ( 4.7A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-4.6A) | 0.79A | 6drzA-4gbrA:28.8 | 6drzA-4gbrA:30.12 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | THR A 110VAL A 114SER A 204PHE A 262ASN A 265 | CAU A 500 ( 4.0A)CAU A 500 (-3.5A)NoneCAU A 500 (-4.6A)CAU A 500 (-3.4A) | 0.92A | 6h7jA-4gbrA:32.1 | 6h7jA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | THR A 110VAL A 114SER A 204SER A 207ASN A 265 | CAU A 500 ( 4.0A)CAU A 500 (-3.5A)NoneCAU A 500 (-4.1A)CAU A 500 (-3.4A) | 0.97A | 6h7jA-4gbrA:32.1 | 6h7jA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109THR A 110ASP A 113VAL A 114PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.66A | 6h7jA-4gbrA:32.1 | 6h7jA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203PHE A 261PHE A 262TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.68A | 6h7jA-4gbrA:32.1 | 6h7jA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.28A | 6h7jA-4gbrA:32.1 | 6h7jA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | TRP A 109THR A 110VAL A 114SER A 203SER A 207 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A) | 0.94A | 6h7jA-4gbrA:32.1 | 6h7jA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | TRP A 109THR A 110VAL A 114SER A 207ASN A 265 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-3.4A) | 0.98A | 6h7jA-4gbrA:32.1 | 6h7jA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | THR A 110VAL A 114SER A 204PHE A 262ASN A 265 | CAU A 500 ( 4.0A)CAU A 500 (-3.5A)NoneCAU A 500 (-4.6A)CAU A 500 (-3.4A) | 0.91A | 6h7jB-4gbrA:32.8 | 6h7jB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | THR A 110VAL A 114SER A 204SER A 207ASN A 265 | CAU A 500 ( 4.0A)CAU A 500 (-3.5A)NoneCAU A 500 (-4.1A)CAU A 500 (-3.4A) | 0.97A | 6h7jB-4gbrA:32.8 | 6h7jB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109THR A 110ASP A 113VAL A 114PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.65A | 6h7jB-4gbrA:32.8 | 6h7jB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203PHE A 261PHE A 262TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.68A | 6h7jB-4gbrA:32.8 | 6h7jB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.27A | 6h7jB-4gbrA:32.8 | 6h7jB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | TRP A 109THR A 110VAL A 114SER A 203SER A 207 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A) | 0.96A | 6h7jB-4gbrA:32.8 | 6h7jB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | TRP A 109THR A 110VAL A 114SER A 207ASN A 265 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-3.4A) | 0.98A | 6h7jB-4gbrA:32.8 | 6h7jB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_A_Y00A406_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109ASP A 113VAL A 114SER A 207TRP A 285TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)NoneCAU A 500 (-4.6A) | 1.26A | 6h7lA-4gbrA:32.3 | 6h7lA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_A_Y00A406_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109THR A 110ASP A 113VAL A 114ASN A 265ASN A 284TRP A 285TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)NoneCAU A 500 (-4.6A) | 0.73A | 6h7lA-4gbrA:32.3 | 6h7lA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_A_Y00A406_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203SER A 207 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A) | 0.87A | 6h7lA-4gbrA:32.3 | 6h7lA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_A_Y00A406_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203TRP A 285TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)NoneCAU A 500 (-4.6A) | 0.76A | 6h7lA-4gbrA:32.3 | 6h7lA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_A_Y00A406_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 207ASN A 265 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-3.4A) | 0.94A | 6h7lA-4gbrA:32.3 | 6h7lA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_A_Y00A406_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 4 / 6 | GLY A 90VAL A 117PHE A 193PHE A 262 | NoneCAU A 500 (-4.2A)CAU A 500 (-4.5A)CAU A 500 (-4.6A) | 0.66A | 6h7lA-4gbrA:32.3 | 6h7lA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_A_Y00A406_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 4 / 6 | GLY A 90VAL A 117PHE A 261PHE A 262 | NoneCAU A 500 (-4.2A)CAU A 500 (-4.2A)CAU A 500 (-4.6A) | 0.46A | 6h7lA-4gbrA:32.3 | 6h7lA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_B_Y00B405_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109ASP A 113VAL A 114SER A 207TRP A 285TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)NoneCAU A 500 (-4.6A) | 1.27A | 6h7lB-4gbrA:32.6 | 6h7lB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_B_Y00B405_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109THR A 110ASP A 113VAL A 114ASN A 265ASN A 284TRP A 285TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)NoneCAU A 500 (-4.6A) | 0.73A | 6h7lB-4gbrA:32.6 | 6h7lB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_B_Y00B405_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203SER A 207 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)CAU A 500 (-4.1A) | 0.88A | 6h7lB-4gbrA:32.6 | 6h7lB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_B_Y00B405_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 203TRP A 285TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-3.3A)NoneCAU A 500 (-4.6A) | 0.76A | 6h7lB-4gbrA:32.6 | 6h7lB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_B_Y00B405_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 207ASN A 265 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-3.4A) | 0.93A | 6h7lB-4gbrA:32.6 | 6h7lB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_B_Y00B405_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 4 / 6 | GLY A 90VAL A 117PHE A 193PHE A 262 | NoneCAU A 500 (-4.2A)CAU A 500 (-4.5A)CAU A 500 (-4.6A) | 0.68A | 6h7lB-4gbrA:32.6 | 6h7lB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7L_B_Y00B405_1 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 4 / 6 | GLY A 90VAL A 117PHE A 261PHE A 262 | NoneCAU A 500 (-4.2A)CAU A 500 (-4.2A)CAU A 500 (-4.6A) | 0.46A | 6h7lB-4gbrA:32.6 | 6h7lB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7M_A_68HA504_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 10 / 12 | TRP A 109THR A 110ASP A 113VAL A 114PHE A 193PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.5A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.61A | 6h7mA-4gbrA:32.5 | 6h7mA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7M_A_68HA504_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 10 / 12 | TRP A 109THR A 110ASP A 113VAL A 114PHE A 193SER A 203PHE A 261PHE A 262ASN A 284TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.72A | 6h7mA-4gbrA:32.5 | 6h7mA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7M_A_68HA504_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109THR A 110ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.29A | 6h7mA-4gbrA:32.5 | 6h7mA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7M_A_68HA504_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109THR A 110VAL A 114PHE A 193SER A 207PHE A 261ASN A 265 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.5A)CAU A 500 (-4.5A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-3.4A) | 0.83A | 6h7mA-4gbrA:32.5 | 6h7mA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7M_A_68HA504_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | VAL A 117PHE A 261ASN A 265ASN A 284TYR A 288 | CAU A 500 (-4.2A)CAU A 500 (-4.2A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 1.38A | 6h7mA-4gbrA:32.5 | 6h7mA-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7M_B_68HB405_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | TRP A 109ASP A 113VAL A 114SER A 207PHE A 262TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.1A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 1.29A | 6h7mB-4gbrA:32.8 | 6h7mB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7M_B_68HB405_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 10 / 12 | TRP A 109ASP A 113VAL A 114VAL A 117PHE A 193PHE A 261PHE A 262ASN A 265ASN A 284TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.5A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.64A | 6h7mB-4gbrA:32.8 | 6h7mB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7M_B_68HB405_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 10 / 12 | TRP A 109ASP A 113VAL A 114VAL A 117PHE A 193SER A 203PHE A 261PHE A 262ASN A 284TYR A 288 | NoneCAU A 500 (-3.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.5A)CAU A 500 (-3.3A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.75A | 6h7mB-4gbrA:32.8 | 6h7mB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7M_B_68HB405_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109VAL A 114VAL A 117PHE A 193SER A 207PHE A 261PHE A 262ASN A 265 | NoneCAU A 500 (-3.5A)CAU A 500 (-4.2A)CAU A 500 (-4.5A)CAU A 500 (-4.1A)CAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A) | 0.82A | 6h7mB-4gbrA:32.8 | 6h7mB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6H7M_B_68HB405_0 (BETA-1 ADRENERGICRECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 5 / 12 | VAL A 117PHE A 261ASN A 265ASN A 284TYR A 288 | CAU A 500 (-4.2A)CAU A 500 (-4.2A)CAU A 500 (-3.4A)CAU A 500 (-3.3A)CAU A 500 (-4.6A) | 1.38A | 6h7mB-4gbrA:32.8 | 6h7mB-4gbrA:59.76 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6IBL_A_H98A501_0 (THIOREDOXIN 1,BETA-1ADRENERGIC RECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 10 / 12 | TRP A 109THR A 110VAL A 114VAL A 117ASP A 192PHE A 193TRP A 258PHE A 261PHE A 262TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)NoneCAU A 500 (-4.5A)NoneCAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-4.6A) | 0.72A | 6iblA-4gbrA:32.4 | 6iblA-4gbrA:50.65 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6IBL_A_H98A501_0 (THIOREDOXIN 1,BETA-1ADRENERGIC RECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 10 / 12 | TRP A 109THR A 110VAL A 114VAL A 117ASP A 192TRP A 258PHE A 261PHE A 262ASN A 265TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)NoneNoneCAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-4.6A) | 0.71A | 6iblA-4gbrA:32.4 | 6iblA-4gbrA:50.65 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6IBL_B_H98B501_0 (THIOREDOXIN 1,BETA-1ADRENERGIC RECEPTOR) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 11 / 12 | TRP A 109THR A 110VAL A 114VAL A 117ASP A 192PHE A 193TRP A 258PHE A 261PHE A 262ASN A 265TYR A 288 | NoneCAU A 500 ( 4.0A)CAU A 500 (-3.5A)CAU A 500 (-4.2A)NoneCAU A 500 (-4.5A)NoneCAU A 500 (-4.2A)CAU A 500 (-4.6A)CAU A 500 (-3.4A)CAU A 500 (-4.6A) | 0.80A | 6iblB-4gbrA:32.7 | 6iblB-4gbrA:50.65 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6MXT_A_K5YA1401_0 (ENDOLYSIN, BETA-2ADRENERGIC RECEPTORCHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 6 / 12 | ASP A 192HIS A 268TYR A 280ILE A 281ASN A 284TYR A 288 | NoneNoneNoneNoneCAU A 500 (-3.3A)CAU A 500 (-4.6A) | 1.33A | 6mxtA-4gbrA:34.3 | 6mxtA-4gbrA:100.00 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6MXT_A_K5YA1401_0 (ENDOLYSIN, BETA-2ADRENERGIC RECEPTORCHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109ASP A 192PHE A 261ASN A 265TYR A 280ILE A 281TYR A 288 | NoneNoneCAU A 500 (-4.2A)CAU A 500 (-3.4A)NoneNoneCAU A 500 (-4.6A) | 0.87A | 6mxtA-4gbrA:34.3 | 6mxtA-4gbrA:100.00 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6MXT_A_K5YA1401_0 (ENDOLYSIN, BETA-2ADRENERGIC RECEPTORCHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 7 / 12 | TRP A 109ASP A 192PHE A 261TYR A 280ILE A 281ASN A 284TYR A 288 | NoneNoneCAU A 500 (-4.2A)NoneNoneCAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.79A | 6mxtA-4gbrA:34.3 | 6mxtA-4gbrA:100.00 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6MXT_A_K5YA1401_0 (ENDOLYSIN, BETA-2ADRENERGIC RECEPTORCHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 8 / 12 | TRP A 109VAL A 114ASP A 192PHE A 193PHE A 261TYR A 280ASN A 284TYR A 288 | NoneCAU A 500 (-3.5A)NoneCAU A 500 (-4.5A)CAU A 500 (-4.2A)NoneCAU A 500 (-3.3A)CAU A 500 (-4.6A) | 0.74A | 6mxtA-4gbrA:34.3 | 6mxtA-4gbrA:100.00 | ||
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target. | 6MXT_A_K5YA1401_0 (ENDOLYSIN, BETA-2ADRENERGIC RECEPTORCHIMERA) |
4gbr | BETA-2 ADRENERGICRECEPTOR (Homosapiens) | 9 / 12 | TRP A 109VAL A 114VAL A 117ASP A 192PHE A 193PHE A 261ASN A 265TYR A 280TYR A 288 | NoneCAU A 500 (-3.5A)CAU A 500 (-4.2A)NoneCAU A 500 (-4.5A)CAU A 500 (-4.2A)CAU A 500 (-3.4A)NoneCAU A 500 (-4.6A) | 0.78A | 6mxtA-4gbrA:34.3 | 6mxtA-4gbrA:100.00 |